Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.

Future Oncology
Shambavi RichardSundar Jagannath

Abstract

The progression of multiple myeloma is accompanied by complex cytogenetic and epigenetic alterations that include mutation or functional inactivation of tumor suppressor proteins and overexpression of oncoproteins. Patients whose myeloma is refractory to the three major classes of drugs including immunomodulatory agents, proteasome inhibitors and anti-CD38 monoclonal antibodies have a very poor prognosis. Drugs with novel mechanisms of action that can bypass resistance mechanisms are sorely needed for this group of patients. Selinexor represents a novel, oral agent with an innovative mechanism of action that offers a significant therapeutic advance in this group of heavily treated patients. Moreover, this novel mechanism may provide additional options for patients with less refractory disease.

References

Mar 9, 2005·Trends in Cell Biology·Ulrike Kutay, Stephan Güttinger
Nov 1, 2006·The Journal of Cell Biology·Biljana CuljkovicKatherine L B Borden
Jan 26, 2007·Nature·Norman E Sharpless, Ronald A DePinho
Jul 10, 2007·Cancer Research·Roland H StauberShirley K Knauer
Aug 19, 2008·Molecular Cancer Research : MCR·Stephanie MarkovinaShigeki Miyamoto
Apr 3, 2009·Nature Structural & Molecular Biology·Xiuhua DongYuh Min Chook
Jan 3, 2012·Biochemical Pharmacology·Joel G TurnerDaniel M Sullivan
Jul 27, 2012·Molecular Biology of the Cell·Darui XuYuh Min Chook
Aug 21, 2012·Cell Reports·Biljana Culjkovic-KraljacicKatherine L B Borden
Oct 12, 2012·Journal of Computer-aided Molecular Design·Ori KalidSharon Shacham
Apr 9, 2013·Blood·Kensuke KojimaMichael Andreeff
Nov 21, 2013·Biomarker Research·Shuqing Lü, Jianmin Wang
Mar 19, 2014·Seminars in Cancer Biology·Joel G TurnerDaniel M Sullivan
Apr 20, 2014·Cancer Discovery·David S P TanAlbiruni R Abdul Razak
Apr 24, 2014·Seminars in Cancer Biology·William T SenapedisYosef Landesman
Jul 16, 2014·Clinical Lymphoma, Myeloma & Leukemia·Kevin B KnopfRaymond L Comenzo
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Sep 23, 2014·American Journal of Physiology. Renal Physiology·Matthew TanRobert H Weiss
Dec 6, 2014·Journal of Hematology & Oncology·Giovanni Luca GravinaClaudio Festuccia
Mar 10, 2015·Experimental Hematology & Oncology·Arundhati DasDelong Liu
Sep 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabio ConfortiGiuseppe Giaccone
Mar 5, 2016·Molecular Cancer Therapeutics·Shirong LiSuzanne Lentzsch
Apr 27, 2016·Pharmacology & Therapeutics·Amit Mahipal, Mokenge Malafa
Jun 22, 2016·Cancer Research·Andrew FeberJohn D Kelly
Mar 21, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jayasree S NairGary K Schwartz

❮ Previous
Next ❯

Citations

Sep 14, 2020·Asia-Pacific Journal of Clinical Oncology·Yang Bai, Xing Su
Dec 31, 2020·Cancers·Katherine L B Borden

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
xenograft

Clinical Trials Mentioned

NCT01607892
NCT02336815
NCT02199665
NCT02343042
NCT02186834
NCT02831686
NCT02780609
NCT03589222
NCT03110562

Software Mentioned

STORM

Related Concepts

Related Feeds

Autophagy & Aging: Inhibitors

The feed focuses on the role of nuclear export inhibitors and their effect on autophagy and the aging process.

Related Papers

The New England Journal of Medicine
Kenar D Jhaveri, Rimda Wanchoo
The New England Journal of Medicine
Ajai ChariSundar Jagannath
Nature Reviews. Clinical Oncology
Diana Romero
© 2022 Meta ULC. All rights reserved